GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3266)

  • GC74187 structure
    GC74187Salicylic acid-13C6
    CAS: 1189678-81-6
    Purity: >97.00%

    Salicylic acid-13C6는 13c로 표기된 살리실산이다.

  • GC74252 structure
    GC74252Euphornin
    CAS: 80454-47-3
    Purity: >98.00%

    Euphornin는 E. helioscopia에서 분리될 수 있는 항산화제이다.

  • GC74256 structure
    GC74256Condurango glycoside A
    CAS: 11051-90-4
    Purity: >95.00%

    Condurango glycoside A 는 p53의 활성제입니다.

  • GC74267 structure
    GC74267Propylparaben-d4
    CAS: 1219802-67-1
    Purity: >99.00%

    Propylparaben-d4 는 듀테륨 표기 니퍼 프로판이다.

  • GC74270 structure
    GC74270Penduletin
    CAS: 569-80-2
    Purity: >99.00%

    Penduletin 는 플라스마와 가시나무에서 분리 될 수있는 플라보노이드 화합물입니다.

  • GC74305 structure
    GC74305CD24/Siglec-10 blocking peptide, CSBP
    Purity: >99.00%

    CD24/Siglec-10 blocking peptide, CSBP은 CD24/Siglec-10 뿐만 아니라 PD-1/PD-L1의 상호작용을 차단할 수 있다.

  • GC74313 structure
    GC74313MYBMIM
    Purity: >99.00%

    MYBMIM는 분자 MYB:CBP/P300 복합체의 조립을위한 억제제입니다.

  • GC74358 structure
    GC74358PNC-27 acetate
    Purity: >99.00%

    PNC-27 acetate, 키메릭 p53-침투성 펩타이드가 p53 펩타이드와 비슷한 구조로 HDM-2에 결합하고, 선택적인 막-세공 형성을 유도하고 암세포 용해를 유도한다.

  • GC74380 structure
    GC74380Ac-VRPR-AMC TFA
    Purity: >99.00%

    Ac-VRPR-AMC TFA는 fluorogenic metacaspase 기질입니다.

  • GC74422 structure
    GC74422Duvakitug
    CAS: 2750005-84-4
    Purity: >99.00%

    Duvakitug은 서였 IgG1-2 λ 단일 클론 항체 TNFSF15/TL1A을 겨냥하고 있다.

  • GC74424 structure
    GC74424Boserolimab
    CAS: 2444297-08-7
    Purity: >99.00%

    Boserolimab (MK-5890) 는 CD27과 결합하여 공동 자극 신호를 제공하여 T세포가 매개하는 반응을 강화하는 인적 흥분제 단일 클론 항체이다.

  • GC74430 structure
    GC74430Exlinkibart
    CAS: 2642171-64-8
    Purity: >99.00%

    Exlinkibart (LVGN-6051) TNFRSF를 표적으로 하며, 상호보완결정구(CDR)를 통한 기술인 유래식 IgG1항체이다.

  • GC74441 structure
    GC74441Evunzekibart
    CAS: 2639688-77-8
    Purity: >97.00%

    Evunzekibart (ATOR-1017)은 Fc-γ 수용체 항체 조건부 4-1BB 효능 제이 및 IgG4-type.

  • GC74449 structure
    GC74449Vonsetamig
    CAS: 2408319-33-3
    Purity: >95.00%

    Vonsetamig는 인간화 면역 글로불린 G4-kappa, 항 tnfrsf17 및 CD3E 단일 클론 항체이다.

  • GC74460 structure
    GC74460Visugromab
    CAS: 2556646-63-8
    Purity: >98.00%

    Visugromab (CTL-002)는 IgG4 mAb를 중화하는 GDF-15입니다.

  • GC74462 structure
    GC74462Zimberelimab
    CAS: 2259860-24-5
    Purity: >99.00%

    Zimberelimab (GLS-010) 는 완전한 인간 IgG4 항 PD-1 단일 클론 항체로서 인간 PD-1에 대한 EC50은 210pM입니다.

  • GC74464 structure
    GC74464Cadonilimab
    CAS: 2394841-59-7
    Purity: >99.00%

    Cadonilimab (AK104) 는 PD1/CTLA4를 표적으로 하는 휴먼 소스 4가 IgG1 이중 특이성 항체이다.

  • GC74467 structure
    GC74467Cemiplimab
    CAS: 1801342-60-8
    Purity: >99.00%

    Cemiplimab (항인 PD-1) 는 PD-1 / PD-L1 매개 T세포 억제를 차단하는 고친화 프로그램적 사망 수용체-1 (PD-1) 단일 클론 IgG4 항체이다.

  • GC74469 structure
    GC74469Tabalumab
    CAS: 1143503-67-6
    Purity: >98.00%

    Tabalumab (LY2127399)는 막 결합 및 가용성 BAFF에 대한 중화 활성을 갖는 인간 항 BAFF (B-cell activating factor) 단일 클론 항체 (IgG4 type)이다.

  • GC74472 structure
    GC74472Conatumumab
    CAS: 896731-82-1
    Purity: >98.00%

    Conatumumab (AMG 655) 는 사람 사망 수용체 5 (DR5, TRAILR2) 에 대한 사람 단일 클론 흥분제 항체 (Kd: 1nM 의 긴 형태 DR5, 0.8nM 의 짧은 형태 DR5) 입니다.

  • GC74476 structure
    GC74476Seribantumab
    CAS: 1334296-12-6
    Purity: >95.00%

    Seribantumab (MM 121)은 HER3를 표적으로 하는 완전 인간 IgG2단일 클론 항체입니다.

  • GC74477 structure
    GC74477Tigatuzumab
    CAS: 918127-53-4
    Purity: >95.00%

    Tigatuzumab (CS-1008)는 사멸 수용체 5 (DR5)를 표적으로 하는 휴머노이드 IgG1 단일 클론 항체이다.

  • GC74482 structure
    GC74482Drozitumab
    CAS: 912628-39-8
    Purity: >99.00%

    Drozitumab (PRO 95780) 는 사망 수용체 DR5를 결합 한 인간 흥분성 단일 클론 항체입니다.

  • GC74486 structure
    GC74486Lexatumumab
    CAS: 845816-02-6
    Purity: >96.00%

    Lexatumumab (HGS-ETR 2)는 일종의 인격동성 TRAIL 수용체 2 (TRAIL-R2, DR5, APO-2) IgG4 형 단일 클론 항체이다.